Pharmbio Korea Co., Ltd.

Quick facts

Marketed products

• OST · Osteoporosis
  OST is an osteoclast inhibitor.

Phase 3 pipeline

• Oral Sulfate Tablet 2-Day · Gastroenterology
  Oral sulfate acts as an osmotic laxative that draws water into the intestinal lumen to promote bowel evacuation.
• PBK-1701TC · Diabetes
  PBK-1701TC is a small molecule that targets the SGLT2 receptor.
• PBK_L2201 · Diabetes
  PBK_L2201 is a small molecule that targets the SGLT2 receptor.
• PBK_M2101 1-Day · Diabetes
  PBK_M2101 1-Day is a small molecule drug that targets the SGLT2 receptor.
• PBK_M2101 2-Day
  PBK_M2101 2-Day is a small molecule that targets the molecular target.
• PBK_M2502 1-Day · unknown
  PBK_M2502 1-Day is a small molecule drug that targets the molecular target.
• PBK_M2502 2-Day · Diabetes
  PBK_M2502 2-Day is a small molecule drug that targets the SGLT2 receptor.

Phase 1 pipeline

• PBK-1801

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Pharmbio Korea Co., Ltd. portfolio CI brief
• Pharmbio Korea Co., Ltd. pipeline updates RSS